Abstract
Objective To investigate the clinical effectiveness of Letrozol and Tamoxifen on endometrium of menopausal patients with breast cancer.Methods The study was performed on 120 breast cancer patients who started undergoing endocrine therapy from 2009 to 2011.All the patients' endometriums were evaluated by transvaginal ultrasound (TVS),hysteroscopy and biopsy before and 1 time a year after endocrine therapy.Results All the patients were evaluated.In tamoxifen group,the endometrial thickness before and 1,2,3 years after tamoxifen therapy were (4.1 ± 0.8),(4.1 ± 0.9),(4.5 ± 0.9) and (4.5 ± 0.9) mm respectively.The endometrial thickness in letrozol group were (4.1 ± 0.8),(3.9 ± 0.8),(3.9 ± 0.8) and (3.9 ± 0.9) mm respectively.6,9,7 patients were found in tamoxifen group 1,2,3 years after tamoxifen therapy having the pathologic changes including endometrial ployp,hyperplasia.3,3,2 patients were found in letrozol group 1,2,3 years after letrozol therapy having the pathologic changes.There was no significant difference in the clinical effectiveness of letrozol group and tamoxifen group.Conclusion The menopausal patients with breast cancer taking tamoxifen are at higher risk of endometrial disease than those taking letrozol.It may be a practical method for the tamoxifen users to be detected by transvaginal ultrasound and hysteroscopy regularly. Key words: Tamoxifen; Letrozol; Endometrium
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
